Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics

Supernus Pharmaceuticals, Inc. (SUPN): $27.58

0.33 (+1.21%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add SUPN to Watchlist
Sign Up

SUPN Price/Volume Stats

Current price $27.58 52-week high $42.09
Prev. close $27.25 52-week low $21.99
Day low $26.81 Volume 328,097
Day high $27.66 Avg. volume 433,011
50-day MA $26.20 Dividend yield N/A
200-day MA $31.88 Market Cap 1.51B

SUPN Stock Price Chart Interactive Chart >

SUPN POWR Grades

  • SUPN scores best on the Value dimension, with a Value rank ahead of 96.96% of US stocks.
  • SUPN's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • SUPN's current lowest rank is in the Sentiment metric (where it is better than 10.4% of US stocks).

SUPN Stock Summary

  • With a one year PEG ratio of 1,190.88, SUPERNUS PHARMACEUTICALS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.88% of US stocks.
  • With a year-over-year growth in debt of -92.26%, SUPERNUS PHARMACEUTICALS INC's debt growth rate surpasses only 1.53% of about US stocks.
  • SUPERNUS PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 27.21%, greater than the shareholder yield of 92.57% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SUPERNUS PHARMACEUTICALS INC are GDRX, CTS, AUID, SPSC, and MITK.
  • Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.

SUPN Valuation Summary

  • In comparison to the median Healthcare stock, SUPN's EV/EBIT ratio is 322.34% higher, now standing at 41.6.
  • SUPN's price/sales ratio has moved down 164.5 over the prior 140 months.

Below are key valuation metrics over time for SUPN.

Stock Date P/S P/B P/E EV/EBIT
SUPN 2023-11-03 2.1 1.5 30.8 41.6
SUPN 2023-11-02 2.1 1.4 30.3 41.0
SUPN 2023-11-01 2.1 1.4 30.1 40.7
SUPN 2023-10-31 2.1 1.4 30.0 40.6
SUPN 2023-10-30 2.0 1.4 29.7 40.2
SUPN 2023-10-27 2.0 1.4 29.7 40.1

SUPN Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -48.75%.
  • Its 4 year revenue growth rate is now at 76.13%.
  • Its 3 year net cashflow from operations growth rate is now at -29.38%.
SUPN's revenue has moved up $266,205,000 over the prior 33 months.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 658.96 138.025 37.672
2022-06-30 630.071 120.074 57.485
2022-03-31 601.349 95.229 73.346
2021-12-31 579.775 127.127 53.424
2021-09-30 564.282 110.297 81.75
2021-06-30 570.953 120.006 100.185

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SUPN has a Quality Grade of B, ranking ahead of 91.1% of graded US stocks.
  • SUPN's asset turnover comes in at 0.375 -- ranking 128th of 682 Pharmaceutical Products stocks.
  • RETA, INVA, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.375 0.860 0.164
2021-03-31 0.370 0.886 0.187
2020-12-31 0.366 0.899 0.196
2020-09-30 0.357 0.920 0.201
2020-06-30 0.343 0.949 0.173
2020-03-31 0.356 0.957 0.155

SUPN Price Target

For more insight on analysts targets of SUPN, see our SUPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.67 (Moderate Buy)

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...

Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has recently seen a significant insider sell by one of its directors.

Yahoo | November 18, 2023

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a […]

Yahoo | November 10, 2023

Q3 2023 Supernus Pharmaceuticals Inc Earnings Call

Q3 2023 Supernus Pharmaceuticals Inc Earnings Call

Yahoo | November 9, 2023

Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | November 9, 2023

Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -323.08% and 8.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2023

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo 15.35%
3-mo -15.11%
6-mo -17.75%
1-year -25.50%
3-year 25.48%
5-year -41.84%
YTD -22.68%
2022 22.33%
2021 15.90%
2020 6.07%
2019 -28.60%
2018 -16.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!